Chronic hepatitis B

Current Treatment Options in Gastroenterology

Volumn 7, Issue 6, 2004, Pages 477-489

  Straley, Stephanie D ^a   Terrault, Norah A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; AMINOTRANSFERASE; AMYLASE; ANTIPYRETIC AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CHAPARRAL EXTRACT; COMFREY EXTRACT; COTRIMOXAZOLE; EARLY ANTIGEN; EMTRICITABINE; GERMANDER EXTRACT; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HERBACEOUS AGENT; IBUPROFEN; INTERFERON; IRON; JIN BU HUAN EXTRACT; KAVA EXTRACT; LAMIVUDINE; LIVER ENZYME; PARACETAMOL; RETINOL; TENOFOVIR; THEOPHYLLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS DNA; ZALCITABINE;

ABDOMINAL PAIN; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANOREXIA; ANTIVIRAL ACTIVITY; ARTICLE; ASTHENIA; BACTERIAL INFECTION; CHRONIC HEPATITIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DIET THERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG APPROVAL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG POTENTIATION; FATIGUE; FEVER; FLU LIKE SYNDROME; FREQUENCY ANALYSIS; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOPHOSPHATEMIA; INFECTION PREVENTION; KIDNEY DYSFUNCTION; LEUKOPENIA; LIFESTYLE; LIVER BIOPSY; LIVER INJURY; LIVER NECROSIS; LIVER TOXICITY; LIVER TRANSPLANTATION; LONG TERM CARE; LUNG FIBROSIS; MENTAL DISEASE; MOLECULAR HYBRIDIZATION; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; PANCREATITIS; PREDICTION; RETINOPATHY; RISK ASSESSMENT; SEROCONVERSION; SIDE EFFECT; THROMBOCYTOPENIA; THYROID DISEASE; TREATMENT OUTCOME; TREATMENT PLANNING; VIRUS DETECTION; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS RESISTANCE; WILD TYPE;

EID: 9744221950     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-004-0007-3     Document Type: Article

References (59)

1. McQuillan G, Coleman P, Kruszon-Moran D, et al.: Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 1999, 89:14-18.
2. Tong MJ, Hwang S-J: Hepatitis B virus infection in Asian Americans. Gastroenterology Clinics of North America 1994, 23:569-579.
3. Lok A, McMahon B: Chronic Hepatitis B - AASLD Practice Guidelines. Hepatology 2001, 34:1225-1241.
4. Hoofnagle J, Dusheiko G, Seeff L, et al.: Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med 1981, 94:744-748.
5. Wong D, Cheung A, O'Rourke K, et al.: Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993, 119:312-323.
6. Brunetto M, Stemier M, Bonino F, et al.: A new hepatitis B virus strain in patients with severe anti-HBe positive chronic hepatitis B. J Hepatol 1990, 10:258-261.
7. Chu C, Keeffe E, Han S, et al.: Prevalence of HBV precore/core promoter variants in the United States. Hepatology 2003, 38:619-628.
8. De Jongh FE, Janssen HLA, De Man RA, et al.: Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992, 103:1630-1635.
9. Yang HI LS, Liaw YF, You SL, et al.: Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Eng J Med 2002, 347:168-174.
10. Beasley R: Hepatitis B. The major etiology of hepato-cellular carcinoma. Cancer 1988, 61:1942-1956.
11. Lok A, Heattcote E, Hoofnagle J: Management of hepatitis B: 2000 - Summary of a Workshop. Gastroenterology 2001, 120: 828-1853.
12. Canadian Association for the Study of the Liver: Management of Viral Hepatitis: Recommended Guidelines for Physicians. Canadian Association for the Study of the Liver 2000, 1999. Ottawa, Ontario.
13. Sherman M, Peltekian KM: Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: Incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995, 22:432-438.
14. McMahon B, Bulkow L, Harpster A, et al.: Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology 2000, 32:842-846.
15. Frieden T, Ozick L, McCord C, et al.: Chronic liver disease in central Harlem: the role of alcohol and viral hepatitis. Hepatology 1999, 29:883-888.
16. Donato F, Tagger A, Chiesa R, et al.: Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: a case-control study in Italy. Brescia HCC Study. Hepatology 1997, 26:579-584.
17. Yu M, Hsu F, Sheen I, et al.: Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol 1997, 145: 039-1047.
18. Mandishona E, MacPhail A, Gordeuk V, et al.: Dietary iron overload as a risk factor for hepatocellular carcinoma in Black Africans. Hepatology 1998, 27:1563-1566.
19. Lok ASK, McMahon BJ: Chronic hepatitis B. AASLD Practice Guidelines, Hepatology, 2001:1225-1241.
20. Keeffe E, Dieterich DT, Han SH, et al.: A treatment algorithm for the management of chronic hepatitis B virus infection in the U.S. Clin Gastroenterol Hepatol 2004, 2:87-106.
21. Lok AS, McMahon BJ: Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations. Hepatology 2004, 39: 57-861.
22. Manesis E, Hadziyannis S: Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001, 121:101-109.
23. Lampertico P, Del Ninno E, Vigano M, et al.: Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003, 37: 56-763.
24. Renault P, Hoofnagle J: Side effects of alpha interferon. Sem Liver Dis 1989, 9:273-277.
25. Wong JB, Koff RS, Tine F, et al.: Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive hepatitis B. Ann Intern Med 1995, 122:664-675.
26. Dusheiko G, Roberts J: Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal. Hepatology 1995, 22:1863-1873.
27. Dienstag J, Schiff E, Wright T, et al.: Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999, 341:1256-1263.
28. Perrillo F, Lai C, Liaw Y, et al.: Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002, 36:186-194.
29. Yuen MF, Chan TM, Hui CK, et al.: Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001, 34:785-791.
30. Perrillo R, Wright T, Rakela I, et al.: A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001, 33:424-432.
31. Allen M, Deslauriers M, Andrews C, et al.: Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998, 27:1670-1677.
32. Santantonio T, Mazzola M, Iacovazzi T, et al.: Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. Hepatology 2000, 32:300-306.
33. Hadziyannis S, Papatheodoridis G, Dimon E, et al.: Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000, 32: 47-851.
34. Marcellin P, Chang T, Lim S, et al.: Adefovir dipivoxil for the treatment of hepatitis B e antigen positive chronic hepatitis B. New England Journal of Medicine 2003, 348: 08-816.
35. Hadziyannis S, Tassopoulos N, Heathcote E, et al.: Adefovir dipivoxil for the treatment of hepatitis B e antigen negative chronic hepatitis B. N Engl J Med 2003, 348:800-807.
36. Tong M, Shiffman M, Heathcote E, et al.: Long-term safety beyond 48 weeks of adefovir dipivoxil 10 mg once daily for chronic hepatitis B: an integrated analysis of two phase III studies. Digestive Disease Week 2003, A-71.
37. Angus P, Vaughan R, Xiong S, et al.: Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003, 125: 92-297.
38. Locarnini S, Hang H, Westland C, et al.: Resistance surveillance of HBeAg-chronic hepatitis B patients treated for two years with adefovir dipivoxil. 11th International Symposium on Viral Hepatitis and Liver Disease. Sydney, Australia, April 2003.
39. Dore GJ, Cooper DCA, Pozniak AL, et al.: Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naïve and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004, 189:1185-1192.
40. Nelson M, Portsmouth S, Stebbing J, et al.:An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals. AIDS 2003, 17:F7-F10.
41. Gish R, Leung N, Wang C, et al.: Antiviral Activity, Safety, and Incidence of Resistance in chronically Infected Hepatitis B Patients Given Once Daily Emtricitabine for 2 Years. Hepatology 2002, 36:372A.
42. Yao F, Terrault N, Freise C, et al.: Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: A comparative study using a matched, untreated cohort. Hepatology 2001, 34:411-416.
43. Mutimer D, Hann H, Buti M, et al.: Significant Clinical Improvement Following the Addition of Adefovir Dipivoxil to Lamivudine in Decompensated Patients with YMD Variant HBV and a Reduced Response to Lamivudine - 1 Year Results. Hepatology 2002, 36: 25A.
44. Hoofnagle J, DiBisceglie A, Waggoner J, et al.: Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 1993, 104:1116-1121.
45. Schiff E, Lai C, Virchow C, et al.: Adefovir Dipivoxil for the Treatment of Chronic Hepatitis B in Patients Pre- and Post-Liver Transplantation with Lamivudine Resistant Hepatitis B Virus Patients. Hepatology 2002, 36:371A.
46. Terrault N: Hepatitis B and Liver Transplantation. Clin Liver Dis 1999, 3:389-416.
47. Schalm S, Heathcote J, Cianciara J, et al.: Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000, 46:562-568.
48. Schiff E, Dienstag J, Karayalcin S, et al.: Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol 2003, 38:818-26.
49. Barbarini G, Zechini F, Pellicelli A, et al.: Long-Term Efficacy of Interferon Alpha-2b and Lamivudine in Combination Compared to Lamivudine Monotherapy in Patients With Chronic Hepatitis B An Italian Multicenter Randomized Trial. Hepatology 2001, 34: 18A.
50. Torresi J, Locarnini S: Antiviral chemotherapy for the treatment of hepatitis B virus infections. Gastroenterology 2000, 118(Suppl 1):S83-S103.
51. Marcellin P, Lau GK, Bonino F et al.: Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004, 351:1206-1217.
52. Peters MG, Hann HWH, Martin P, et al.: Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004, 1126:91-101.
53. Lai C, Rosmawati M, Lao J. et al.: Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002, 123: 831-1838.
54. Colonno R, Rose R: Genotypic Analysis Following 48 Week Entecavir Treatment of Chronic HBV Subjects Failing Lamivudine Suggests Sustained Susceptibility and Lack of Resistance Development. Hepatology 2002, 36:644A.
55. Tassopoulos N, Hadziyannis S, Cianciara J, et al.: Entecavir is Effective in Treating Patients With Chronic Hepatitis B Who Have Failed Lamivudine Therapy. Hepatology 2001, 34:340A.
56. Cooksley W, Piratvisuth T, Lee SD, et al.: Peginterferon Alfa-2a (40KDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepatitis 2003, 10:298-305.
57. Park J, Braun J, Goldman D, et al.: Co-Infection With HIV and HBV. The Effect of Tenofovir Disoproxil Fumarate in Lamivudine and Famciclovir Experienced Patients. Hepatology 2002, 36:641A.
58. Cecil B: Tenofovir 300 mg Daily is Effective in Patients With Chronic HBV Who Fail Lamivudine. Hepatology 2002, 36: 30A.
59. Nunez M, Garcia-Samaniego I, Perez-Olmeda M, et al.: Therapy With Tenofovir in HBV/HIV Co-Infected Patients With Resistance or Partial Response to Lamivudine. Hepatology 2002, 36:636A.